Management of anticoagulation and hemostasis for pediatric extracorporeal membrane oxygenation

Clinics in Laboratory Medicine

Volumn 34, Issue 3, 2014, Pages 655-673

  Saini, Arun ^a   Spinella, Philip C ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulation; Congenital heart defect; Extracorporeal membrane oxygenation; Heparin; Platelet function; Thromboelastography

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; ARGATROBAN; BLOOD CLOTTING FACTOR; CLOPIDOGREL; DANAPAROID; DIPYRIDAMOLE; FIBRINOGEN; FONDAPARINUX; HEPARIN; HEPARIN LYASE; HIRULOG; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LEPIRUDIN; PENTOXIFYLLINE; PLACEBO; PROTHROMBIN COMPLEX; RECOMBINANT ANTITHROMBIN III; RECOMBINANT BLOOD CLOTTING FACTOR 7; THROMBIN; TRANEXAMIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTICOAGULANT AGENT; HEMOSTATIC AGENT;

ACTIVATED CLOTTING TIME; ALGORITHM; ALLERGIC REACTION; ANTICOAGULANT THERAPY; ANTICOAGULATION; ASSAY; BLEEDING; BLOOD CLOTTING DISORDER; CONTINUOUS INFUSION; CRYOPRECIPITATE; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; ECMO INDUCED COAGULOPATHY; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE TRANSFUSION; EXTRACORPOREAL OXYGENATION; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INFLAMMATION; INTERNATIONAL NORMALIZED RATIO; KIDNEY INJURY; LEUKOCYTE COUNT; NEUROLOGIC DISEASE; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PLASMA TRANSFUSION; POINT OF CARE TESTING; PRIORITY JOURNAL; REVIEW; ROTEM GUIDED ALGORITHM; SEIZURE; SINGLE DRUG DOSE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT INDICATION; VASODILATATION; ADVERSE EFFECTS; BLOOD CLOTTING; CHEMICALLY INDUCED; CHILD; DRUG EFFECTS; DRUG MONITORING; EVIDENCE BASED MEDICINE; HEMORRHAGE; ORAL DRUG ADMINISTRATION; PEDIATRICS; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PROCEDURES; THROMBOSIS;

ADMINISTRATION, ORAL; ALGORITHMS; ANTICOAGULANTS; BLOOD COAGULATION; CHILD; DRUG MONITORING; EVIDENCE-BASED MEDICINE; EXTRACORPOREAL MEMBRANE OXYGENATION; HEMORRHAGE; HEMOSTASIS; HEMOSTATICS; HUMANS; INDIVIDUALIZED MEDICINE; PEDIATRICS; PRACTICE GUIDELINES AS TOPIC; THROMBOSIS;

EID: 84906934697     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2014.06.014     Document Type: Review

References (81)

1. Monagle P., Newall F. Anticoagulation in children. Thromb Res 2012, 130:142-146.
2. Monagle P., Newall F., Campbell J. Anticoagulation in neonates and children: pitfalls and dilemmas. Blood Rev 2010, 24:151-162.
3. International summary, extracorporeal life support organization registry report. 2013. Available at: Accessed January 20, 2014. http://elsonet.org.
4. Paden M.L., Conrad S.A., Rycus P.T., et al. Extracorporeal life support organization registry report 2012. ASAIO J 2013, 59:202-210.
5. Hoffman M., Monroe D.M. Acell-based model of hemostasis. Thromb Haemost 2001, 85:965-968.
6. Despotis G.J., Avidan M.S., Hogue C.W. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg 2001, 72:S1821-S1831.
7. Eaton M.P., Lannoli E.M. Coagulation considerations for infants and children undergoing cardiopulmonary bypass. Paediatr Anaesth 2011, 21:31-42.
8. Oliver W.C. Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth 2009, 13:154-175.
9. Edmunds L.H., Colman R.W. Thrombin during cardiopulmonary bypass. Ann Thorac Surg 2006, 82:2315-2322.
10. Seghaye M.C., Duchateau J., Grabitz R.G., et al. Complement activation during cardiopulmonary bypass in infants and children. Relation to postoperative multiple system organ failure. JThorac Cardiovasc Surg 1993, 106:978-987.
11. Risnes I., Wagner K., Ueland T., et al. Interleukin-6 may predict survival in extracorporeal membrane oxygenation treatment. Perfusion 2008, 23:173-178.
12. Peek G.J., Firmin R.K. The inflammatory and coagulative response to prolonged extracorporeal membrane oxygenation. ASAIO J 1999, 45:250-263.
13. Butenas S., Orfeo T., Mann K.G. Tissue factor activity and function in blood coagulation. Thromb Res 2008, 122(Suppl 1):S42-S46.
14. De Somer F., Van Belleghem Y., Caes F., et al. Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass. JThorac Cardiovasc Surg 2002, 123:951-958.
15. Peng Z., Pati S., Potter D., et al. Fresh frozen plasma lessens pulmonary endothelial inflammation and hyperpermeability after hemorrhagic shock and is associated with loss of syndecan 1. Shock 2013, 40:195-202.
16. Pati S., Matijevic N., Doursout M.F., et al. Protective effects of fresh frozen plasma on vascular endothelial permeability, coagulation, and resuscitation after hemorrhagic shock are time dependent and diminish between days 0 and 5 after thaw. JTrauma 2010, 69:S55-S63.
17. Kozar R.A., Peng Z., Zhang R., et al. Plasma restoration of endothelial glycocalyx in a rodent model of hemorrhagic shock. Anesth Analg 2011, 112:1289-1295.
18. Cheung P.Y., Sawicki G., Salas E., et al. The mechanisms of platelet dysfunction during extracorporeal membrane oxygenation in critically ill neonates. Crit Care Med 2000, 28:2584-2590.
19. Straub A., Wendel H.P., Dietz K., et al. Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation. Thromb Haemost 2008, 99:609-615.
20. Michelson A.D. Thrombin-induced down-regulation of the platelet membrane glycoprotein Ib-XI complex. Semin Thromb Hemost 1992, 18:18-27.
21. Saini A., Doctor A., Gazit A., et al. Platelet inhibition is associated with severe bleeding and mortality in children on ECLS. Crit Care Med 2013, 41(Suppl):760.
22. Chung A., Wildhirt S.M., Wang S., et al. Combined administration of nitric oxide gas and iloprost during cardiopulmonary bypass reduces platelet dysfunction: a pilot clinical study. JThorac Cardiovasc Surg 2005, 129:782-790.
23. Wesley M.C., McGowan F.X., Castro R.A., et al. The effect of milrinone on platelet activation as determined by TEG platelet mapping. Anesth Analg 2009, 108:1425-1429.
24. Reilly T.M., Forsythe M.S., Racanelli A.L., et al. Recombinant plasminogen activator inhibitor-1 protects platelets against the inhibitory effects of plasmin. Thromb Res 1993, 71:61-68.
25. Bembea M.M., Annich G., Rycus P., et al. Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey. Pediatr Crit Care Med 2013, 14:e77-e84.
26. Owings J.T., Pollock M.E., Gosselin R.C., et al. Anticoagulation of children undergoing cardiopulmonary bypass is overestimated by current monitoring techniques. Arch Surg 2000, 135:1042-1047.
27. Despotis G.J., Summerfield A.L., Joist J.H., et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. JThorac Cardiovasc Surg 1994, 108:1076-1082.
28. Martindale S.J., Shayevitz J.R., D'Errico C. The activated coagulation time: suitability for monitoring heparin effect and neutralization during pediatric cardiac surgery. JCardiothorac Vasc Anesth 1996, 10:458-463.
29. Guzzetta N.A., Baja T., Fazlollah T., et al. Acomparison of heparin management strategies in infants undergoing cardiopulmonary bypass. Anesth Analg 2008, 106:419-425.
30. Nankervis C.A., Preston T.J., Dysart K.C., et al. Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation. ASAIO J 2007, 53:111-114.
31. Bembea M.M., Schwartz J.M., Shah N., et al. Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation. ASAIO J 2013, 59:63-68.
32. Muntean W. Coagulation and anticoagulation in extracorporeal membrane oxygenation. Artif Organs 1999, 23:979-983.
33. ELSO Guidelines for Cardiopulmonary Extracorporeal Life Support Extracorporeal Life Support Organization, Version 1.3. Ann Arbor (MI): 2013. p. 13. Anticoagulation. Available at: Accessed January 24, 2014. http://www.elsonet.org.
34. Baired C.W., Zurakowski D., Robinson B., et al. Anticoagulation and pediatric extracorporeal membrane oxygenation: impact of activated clotting time and heparin dosing on survival. Ann Thorac Surg 2007, 83:912-919.
35. Ignjatovic V., Summerhayes R., Gan A., et al. Monitoring unfractioned heparin therapy: which anti-factor Xa assay is appropriate?. Thromb Res 2007, 120:347-351.
36. Lehman C.M., Rettmann J.A., Wilson L.W., et al. Comparative performance of three anti-factor Xa heparin assays in patients in a medical intensive care unit receiving intravenous, unfractionated heparin. Am J Clin Pathol 2006, 126:416-421.
37. Krulder J.W., Strebus A.F., Meinders A.E., et al. Anticoagulant effect of unfractionated heparin in antithrombin-depleted plasma invitro. Haemostasis 1996, 26:85-89.
38. Hirsh J., Rascheke R., Warkentin T.E., et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995, 108(Suppl 4):258S-275S.
39. Chen A., Teruya J. Global hemostasis testing thromboelastography: old technology, new applications. Clin Lab Med 2009, 29:391-407.
40. Whiting D., Dinardo J.A. TEG and ROTEM: technology and clinical application. Am J Hematol 2014, 10.1002/ajh.23599.
41. Chan K.L., Summerhayes R.G., Ignjatovic V., et al. Reference values for kaolin- activated thromboelastography in healthy children. Anesth Analg 2007, 105:1610-1613.
42. Weber C.F., Görlinger K., Meininger D., et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 2012, 117:531-547.
43. Westbrook A.J., Olsen J., Bailey M., et al. Protocol based on thromboelastograph (TEG) outperforms physician preference using laboratory coagulation tests to guide blood replacement during and after cardiac surgery: a pilot study. Heart Lung Circ 2009, 18:277-288.
44. Girdauskas E., Kempfert J., Kuntze T., et al. Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: a prospective, randomized trial. JThorac Cardiovasc Surg 2010, 140:1117-1124.
45. Grölinger K., Bergmann L., Dirkmann D. Coagulation management in patients undergoing mechanical circulatory support. Best Pract Res Clin Anaesthesiol 2012, 26:179-198.
46. Rutledge J.M., Chakravarti S., Massicotte M.P., et al. Antithrombotic strategies in children receiving long-term Berlin Heart EXCOR ventricular assist device therapy. JHeart Lung Transplant 2013, 32:569-573.
47. Griffith M.J. Kinetics of the heparin-enhanced antithrombin III/thrombin reaction. Evidence for a template model for the mechanism of action of heparin. JBiol Chem 1982, 257:7360-7365.
48. Newall F., Ignjatovic V., Johnston L., et al. Age is a determinant factors for measures of concentration and effect in children requiring unfractionated heparin. Thromb Haemost 2010, 103:1085-1090.
49. Yee D.L., O'Brien S.H., Young G. Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients. Clin Pharmacokinet 2013, 52:967-980.
50. Weitz J.I., Crowther M. Direct thrombin inhibitors. Thromb Res 2002, 106:275-284.
51. Ranucci M., Ballotta A., Kandil H., et al. Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. Crit Care 2011, 15:R275. 10.1186/cc10556.
52. Pieri M., Agracheva N., Bonaveglio E., et al. Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation: a case-control study. JCardiothorac Vasc Anesth 2013, 27:30-34.
53. Hursting M.J., Dubb J., Verme-Gibboney C.N. Argatroban anticoagulation in pediatric patients: a literature analysis. JPediatr Hematol Oncol 2006, 28:4-10.
54. Scott K.L., Grier L.R., Conrad S.A. Heparin-induced thrombocytopenia in a pediatric patient receiving extracorporeal support and treated with argatroban. Pediatr Crit Care Med 2006, 7:255-257.
55. Deitcher S.R., Topoulos A.P., Bartholomew J.R., et al. Lepirudin anticoagulation for heparin-induced thrombocytopenia. JPediatr 2002, 140:264-266.
56. Moffett B.S., Cabrera A.G., Teruva J., et al. Anticoagulation therapy trends in children supported by ventricular assist devices: a multi-institutional study. ASAIO J 2014, 10.1097/MAT. 0000000000000037.
57. Bidlingmaier C., Magnani H., Girisch M., et al. Safety and efficacy of danaparoid (Orgaran) use in children. Acta Haematol 2006, 115:237-247.
58. Malherbe S., Tsui B.C., Stobart K., et al. Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. Anesthesiology 2004, 100:443-445.
59. Ciccolo M.L., Bernstein J., Collazos J.C., et al. Argatroban anticoagulation for cardiac surgery with cardiopulmonary bypass in an infant with double outlet right ventricle and a history of heparin-induced thrombocytopenia. Congenit Heart Dis 2008, 3:299-302.
60. Bauer C., VIchova Z., Ffrench P., et al. Extracorporeal membrane oxygenation with danaparoid sodium after massive pulmonary embolism. Anesth Analg 2008, 106:1101-1103.
61. Beiderlinden M., Treschan T., Gorlinger K., et al. Argatroban in extracorporeal membrane oxygenation. Artif Organs 2007, 31:461-465.
62. Knoderer C.A., Knoderer H.M., Turrentine M.W., et al. Lepirudin anticoagulation for heparin-induced thrombocytopenia after cardiac surgery in a pediatric patient. Pharmacotherapy 2006, 26:709-712.
63. Agati S., Ciccarello G., Salvo D., et al. Use of a novel anticoagulation strategy during ECMO in a pediatric population: single-center experience. ASAIO J 2006, 52:513-516.
64. Byrnes J.W., Swearingen C.J., Prodhan P., et al. Antithrombin III supplementation on extracorporeal membrane oxygenation: impact on heparin dose and circuit life. ASAIO J 2014, 60(1):57-62.
65. Perry R., Stein J., Young G., et al. Antithrombin III administration in neonates with congenital diaphragmatic hernia during the first three days of extracorporeal membrane oxygenation. JPediatr Surg 2013, 48:1837-1842.
66. Giglia T.M., Massicotte M.P., Tweddell J.S., et al. Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association. Circulation 2013, 128(24):2622-2703.
67. Ortmann E., Besser M.W., Klein A.A. Antifibrinolytic agents in current anesthetic practice. Br J Anaesth 2013, 111:549-563.
68. Li J.S., Yow E., Berezny K.Y., et al. Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children on cLOpidogrel (PICOLO) trial. Circulation 2008, 117:553-559.
69. Downard C.D., Betit P., Chang R.W., et al. Impact of AMICAR on hemorrhagic complications of ECMO: a ten-year review. JPediatr Surg 2003, 38:1212-1216.
70. Horwitz J.R., Cofer B.R., Warner B.W., et al. Amulticenter trial of ε-aminocaproic acid (Amicar) in the prevention of bleeding in infants on ECMO. JPediatr Surg 1998, 33:1610-1613.
71. Long M.T., Wagner D., Maslach-Hubbard A., et al. Safety and efficacy of recombinant activated factor VII for refractory hemorrhage in pediatric patients on extracorporeal membrane oxygenation: a single center review. Perfusion 2014, 29(2):163-170.
72. Niebler R.A., Punzalan R.C., Marchan M., et al. Activated recombinant factor VII for refractory bleeding during extracorporeal membrane oxygenation. Pediatr Crit Care Med 2010, 11:98-102.
73. Walker A., Davidosn M., Chalmers E. Letter to the Editor. Pediatr Crit Care Med 2010, 11:537-538.
74. Okonta K.E., Edwin F., Falase B. Is recombinant activated factor VII effective in the treatment of excessive bleeding after paediatric cardiac surgery. Interact Cardiovasc Thorac Surg 2012, 15:690-694.
75. Franchini M., Lippi G. Prothrombin complex concentrates: an update. Blood Transfuse 2010, 8:149-154.
76. Dohner M.L., Wiedmeyer S.E., Staddard R.A., et al. Very high users of platelet transfusions in the neonatal intensive care unit. Transfusion 2009, 49:869-872.
77. Stiller B., Lemmer J., Merkle F., et al. Consumption of blood products during mechanical circulatory support in children: comparison between ECMO and a pulsatile ventricular assist device. Intensive Care Med 2004, 30:1814-1820.
78. Smith A., Hardison D., Bridges B., et al. Red blood cell transfusion volume and mortality among patients receiving extracorporeal membrane oxygenation. Perfusion 2013, 28:54-60.
79. Thurer R.L., Popvsky M.A. Blood transfusion and the microcirculation. Transfusion 2011, 51:2259-2261.
80. Spinella P.C., Doctor A., Blumberg N., et al. Does the storage duration of blood products affect outcomes in critically ill patients?. Transfusion 2011, 51:1644-1650.
81. Arslan E., Sierko E., Waters J.H., et al. Microcirculatory hemodynamics after acute blood loss followed by fresh and banked blood transfusion. Am J Surg 2005, 190:456-462.